Ginkgo Bioworks

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

Patch Biosciences specializes in the development of machine-designed DNA for gene therapy, leveraging synthetic biology and machine learning. The company has created a platform that engineers genetic medicine vehicles aimed at being effective, specific, and durable, with the potential to target a wide array of diseases. By employing large-scale DNA synthesis, Patch Biosciences aims to enhance the safety and efficacy of gene therapies, ultimately contributing to advancements in healthcare and addressing diverse medical needs.

Reverie Labs is a Boston-based company focused on improving drug development processes for pharmaceutical firms through advanced machine learning techniques. The company utilizes these algorithms to predict the bio physicochemical properties of drug candidates, thereby accelerating preclinical development. Reverie Labs specializes in lead generation and optimization by creating structure-based predictive models that assess the potency of small molecules. It also offers a multi-objective molecular optimizer that generates new molecules while ensuring they maintain both potency and synthesizability. This approach allows for the prioritization and optimization of drug candidates, facilitating their progression to animal and human clinical trials more efficiently.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Altar is a biotechnology company focused on automated fluidics, dedicated to enhancing the performance of microorganisms for commercial applications. They develop proprietary technologies that utilize automated cultivation devices to harness natural selection, allowing for the continuous and contamination-free proliferation of cell suspensions. This innovative approach enables industries to improve the efficacy of microorganisms used in producing food, feed, flavors and fragrances, cosmetics, fuels, chemicals, and health products. By ensuring 24/7 operation, Altar's technology supports the long-term cultivation of microbes, making it a valuable resource for various sectors seeking to optimize their microbial applications.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.

Bitome is a Boston-based company specializing in connected medical devices, focusing on noninvasive hydration monitoring technology. Established two years ago, Bitome's first product is designed to monitor hydration status, with significant applications in fields such as dialysis, diabetes management, sports performance, and maternal/fetal health. One of its primary uses is in assessing volume status in patients with congestive heart failure (CHF), a critical but challenging biometric to measure that is closely linked to patient outcomes. By enhancing hydration monitoring, Bitome aims to revolutionize CHF management in a manner similar to how glucose monitoring transformed diabetes care.

FGen GmbH, founded in 2011 in Basel, Switzerland, specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries. This innovative approach facilitates the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in the biotechnology, life sciences, and pharmaceutical sectors to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on creating optimized microbial strains for various biotechnological applications, utilizing proprietary screening technology alongside biological engineering tools. This enables clients to achieve efficient and cost-competitive production of chemicals and proteins.

Project Beacon COVID-19 is a social benefit organization based in Massachusetts focused on enhancing the capacity, availability, accessibility, and affordability of COVID-19 testing. The organization provides a range of services, including the evaluation of various testing strategies for organizations, managing test logistics, and establishing sample collection sites. Additionally, Project Beacon assists in reporting test results to individuals, organizations, and public health authorities. By facilitating these services, the organization aims to support the safe reopening of society and the return to work, while also addressing disparities in access to testing across the state.

Cambium is a company focused on developing biomaterials for various sectors, including defense, aerospace, and renewable energy. Established in 2019 and located in Berkeley, California, it specializes in advanced materials research and development. The company utilizes a combination of synthetic biology, materials science, and artificial intelligence to enhance material performance and sustainability. Cambium's approach involves vertically integrated innovation, ranging from computational material discovery to the production of advanced composites within the United States. By leveraging cutting-edge advancements across multiple scientific disciplines, Cambium aims to improve existing products and facilitate the creation of next-generation materials.

Dutch DNA is a technology provider specializing in the food, feed, and enzyme industries. The company operates as a contract manufacturing organization, focusing on the development of fungal strains and fermentation processes for protein and organic acid production. It is dedicated to creating tailored biotechnology solutions based on client requirements, offering a platform that facilitates the discovery and production of enzymes and metabolites. This enables medical enterprises to achieve high purity and low production costs in their processes.

Novogy, Inc. is focused on developing bio-based solutions for the production of food, fuel, and chemicals, with a particular emphasis on cellulosic biofuels derived from waste paper sludge. The company employs an innovative technology that integrates molecular biology and process engineering to enhance competitiveness in production processes while minimizing antibiotic use in large-scale operations. Serving various bio-based industries, Novogy distributes its cellulosic biofuels primarily for the transportation sector. Established in 2009 and headquartered in Cambridge, Massachusetts, Novogy operates as a subsidiary of TOTAL S.A.

Allonnia LLC is a biotechnology company based in Boston, Massachusetts, founded in 2019, that specializes in waste remediation services. The company focuses on developing enzymes, proteins, and microbes that effectively degrade or metabolize environmental contaminants, facilitating the recovery and upcycling of valuable materials from waste. Allonnia aims to provide innovative solutions to pressing environmental challenges, including safer water and cleaner mining, while promoting sustainability. Their unique approach integrates biology with advanced technology to create systems that transform waste into useful resources. Allonnia's commitment to environmental stewardship and innovation has garnered industry recognition, positioning it as a leader in the field of biotechnology and waste management.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing genomic technology to discover drugs of natural origin. Founded in 2010, the company utilizes a proprietary genomic search engine and customized search queries to uncover hidden natural products by analyzing their unique genomic signatures. This innovative approach allows researchers to generate novel drug candidates and understand their mechanisms of action, facilitating the conversion of genomic data into potential therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Joyn Bio LLC is a joint venture established by Bayer and Ginkgo Bioworks, focusing on the development of microbial probiotics for plants. Founded in 2017 and headquartered in Boston, Massachusetts, with a research facility in West Sacramento, California, the company aims to tackle significant agricultural challenges. Its primary initiative involves engineering microbes that help cereal crops like corn, wheat, and rice meet their nitrogen needs. This innovation seeks to reduce the agricultural sector's dependence on nitrogen fertilizers, thereby minimizing the environmental impact associated with chemical fertilizer usage. Joyn Bio's multidisciplinary team includes microbiologists, synthetic biologists, plant scientists, and ecologists dedicated to advancing sustainable agricultural practices.

Gen9 is a privately held company based in Cambridge, Massachusetts, focused on advancing synthetic biology to enhance the production of DNA content. Established in 2009 by experts in the field, Gen9 has developed a next-generation gene synthesis technology that enables high-throughput, automated DNA construct production with improved cost efficiency and accuracy compared to traditional methods. The company's innovations aim to support various industries, including enzyme and chemical production, pharmaceuticals, and biofuels, by facilitating the constructive application of synthetic biology techniques to improve genes, pathways, genomes, and organisms.